CD69 and neoplasm: Consistently, a higher proportion of tumor‐infiltrating T cells exhibited expression of the T cell activation marker CD69 and effector molecules GZMB and IFNγ (Figure S6I, Supporting Information) in the combination treatment group as compared with to the control or single drug treatment group.